BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Samaha AA, Mouawia H, Fawaz M, Hassan H, Salami A, Bazzal AA, Saab HB, Al-Wakeel M, Alsaabi A, Chouman M, Moussawi MA, Ayoub H, Raad A, Hajjeh O, Eid AH, Raad H. Effects of a Single Dose of Ivermectin on Viral and Clinical Outcomes in Asymptomatic SARS-CoV-2 Infected Subjects: A Pilot Clinical Trial in Lebanon. Viruses 2021;13:989. [PMID: 34073401 DOI: 10.3390/v13060989] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Mohan A, Tiwari P, Suri TM, Mittal S, Patel A, Jain A, Velpandian T, Das US, Boppana TK, Pandey RM, Shelke SS, Singh AR, Bhatnagar S, Masih S, Mahajan S, Dwivedi T, Sahoo B, Pandit A, Bhopale S, Vig S, Gupta R, Madan K, Hadda V, Gupta N, Garg R, Meena VP, Guleria R. Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): A single-centre randomized, placebo-controlled trial. J Infect Chemother 2021;27:1743-9. [PMID: 34483029 DOI: 10.1016/j.jiac.2021.08.021] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Hazan S, Dave S, Gunaratne AW, Dolai S, Clancy RL, McCullough PA, Borody TJ. Effectiveness of ivermectin-based multidrug therapy in severely hypoxic, ambulatory COVID-19 patients. Future Microbiol 2022. [PMID: 35135310 DOI: 10.2217/fmb-2022-0014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Low ZY, Yip AJW, Lal SK. Repositioning Ivermectin for Covid-19 treatment: Molecular mechanisms of action against SARS-CoV-2 replication. Biochim Biophys Acta Mol Basis Dis 2021;1868:166294. [PMID: 34687900 DOI: 10.1016/j.bbadis.2021.166294] [Reference Citation Analysis]
4 George B, Moorthy M, Kulkarni U, Selvarajan S, Rupali P, Christopher DJ, Balamugesh T, Rose W, Lakshmi KM, Devasia AJ, Fouzia NA, Korula A, Lionel S, Abraham A, Mathews V. Single Dose of Ivermectin is not Useful in Patients with Hematological Disorders and COVID-19 Illness: A Phase II B Open Labelled Randomized Controlled Trial. Indian J Hematol Blood Transfus. [DOI: 10.1007/s12288-022-01546-w] [Reference Citation Analysis]
5 Sabry N, Fouad Y, AbdAllah M, Cordie A, Esmat G. Dose-Dependent Ivermectin Effect on COVID-19 Polymerase Chain Reaction Status. Am J Ther 2022. [PMID: 35383577 DOI: 10.1097/MJT.0000000000001490] [Reference Citation Analysis]
6 Santin AD, Scheim DE, McCullough PA, Yagisawa M, Borody TJ. Ivermectin: a multifaceted drug of Nobel prize-honoured distinction with indicated efficacy against a new global scourge, COVID-19. New Microbes New Infect 2021;43:100924. [PMID: 34466270 DOI: 10.1016/j.nmni.2021.100924] [Reference Citation Analysis]
7 Popp M, Stegemann M, Metzendorf MI, Gould S, Kranke P, Meybohm P, Skoetz N, Weibel S. Ivermectin for preventing and treating COVID-19. Cochrane Database Syst Rev 2021;7:CD015017. [PMID: 34318930 DOI: 10.1002/14651858.CD015017.pub2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
8 Samaha AA, Mouawia H, Fawaz M, Hassan H, Salami A, Bazzal AA, Saab HB, Al-Wakeel M, Alsaabi A, Chouman M, Moussawi MA, Ayoub H, Raad A, Hajjeh O, Eid AH, Raad H. Retraction: Samaha et al. Effects of a Single Dose of Ivermectin on Viral and Clinical Outcomes in Asymptomatic SARS-CoV-2 Infected Subjects: A Pilot Clinical Trial in Lebanon. Viruses 2021, 13, 989. Viruses 2021;13:2154. [PMID: 34751680 DOI: 10.3390/v13112154] [Reference Citation Analysis]
9 Izcovich A, Peiris S, Ragusa M, Tortosa F, Rada G, Aldighieri S, Reveiz L. Bias as a source of inconsistency in ivermectin trials for COVID-19: A systematic review. Ivermectin's suggested benefits are mainly based on potentially biased results. J Clin Epidemiol 2021:S0895-4356(21)00422-4. [PMID: 34933115 DOI: 10.1016/j.jclinepi.2021.12.018] [Cited by in Crossref: 5] [Article Influence: 5.0] [Reference Citation Analysis]
10 Cruciani M, Pati I, Masiello F, Malena M, Pupella S, De Angelis V. Ivermectin for Prophylaxis and Treatment of COVID-19: A Systematic Review and Meta-Analysis. Diagnostics (Basel) 2021;11:1645. [PMID: 34573986 DOI: 10.3390/diagnostics11091645] [Reference Citation Analysis]
11 Khan M, Singh GK, Abrar S, Ganeshan R, Morgan K, Harky A. Pharmacotherapeutic agents for the management of COVID-19 patients with preexisting cardiovascular disease. Expert Opin Pharmacother 2021;:1-20. [PMID: 34464223 DOI: 10.1080/14656566.2021.1960311] [Reference Citation Analysis]
12 Mirahmadizadeh A, Semati A, Heiran A, Ebrahimi M, Hemmati A, Karimi M, Basir S, Zare M, Charlys da Costa A, Zeinali M, Sargolzaee M, Eilami O. Efficacy of single-dose and double-dose ivermectin early treatment in preventing progression to hospitalization in mild COVID-19: A multi-arm, parallel-group randomized, double-blind, placebo-controlled trial. Respirology 2022. [PMID: 35738778 DOI: 10.1111/resp.14318] [Reference Citation Analysis]
13 Bartoletti M, Azap O, Barac A, Bussini L, Ergonul O, Krause R, Paño-Pardo JR, Power NR, Sibani M, Szabo BG, Tsiodras S, Verweij PE, Zollner-Schwetz I, Rodríguez-Baño J. ESCMID COVID-19 Living guidelines: drug treatment and clinical management. Clin Microbiol Infect 2021:S1198-743X(21)00634-0. [PMID: 34823008 DOI: 10.1016/j.cmi.2021.11.007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 17.0] [Reference Citation Analysis]
14 Shafiee A, Teymouri Athar MM, Kohandel Gargari O, Jafarabady K, Siahvoshi S, Mozhgani SH. Ivermectin under scrutiny: a systematic review and meta-analysis of efficacy and possible sources of controversies in COVID-19 patients. Virol J 2022;19:102. [PMID: 35698151 DOI: 10.1186/s12985-022-01829-8] [Reference Citation Analysis]